We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LTM:BCSLATAM Airlines Group SA Analysis

Data as of 2026-03-11 - not real-time

$50.47

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

LATAM Airlines (LTM) trades around $50.46, well below its 20‑day ($55.33) and 50‑day ($58.60) simple moving averages, signaling short‑term weakness, while the 200‑day SMA ($48.21) sits just under price, offering a longer‑term floor. The RSI of 35.7 points to oversold conditions and the MACD histogram remains negative, reinforcing a bearish technical outlook. Fundamentally, the stock appears cheap – the trailing P/E of 10.2 is far under the industry average of 29.3, and the DCF‑derived fair value of $121.3 suggests a potential upside of roughly 40%. Revenue grew 16% YoY in Q4 2025 with passenger revenue up 20%, and the dividend yield of 4.73% (payout ~48%) is attractive given solid operating cash flow. However, the balance sheet is strained: debt‑to‑equity exceeds 600%, ROE is only 1.4%, and leverage raises concerns about long‑term sustainability. Recent analyst activity reflects this split view – Morgan Stanley downgraded to equal‑weight, yet several houses maintain a "Buy" stance with price targets near $70, indicating confidence in the growth narrative despite the risks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering above support at $45.57
  • Bearish MACD and oversold RSI
  • High leverage amplifies downside risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation gap (P/E vs industry, DCF upside)
  • Robust revenue growth and strong cash flow
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term upside to fair‑value estimate of $121.3
  • Strategic network across 27 countries supports future growth
  • Dividend stream provides defensive income component

Key Metrics & Analysis

Financial Health

Revenue Growth16.10%
Profit Margin10.23%
P/E Ratio10.2
ROE142.89%
ROA8.88%
Debt/Equity604.88
P/B Ratio25232.5
Op. Cash Flow$3.7B
Free Cash Flow$1.5B
Industry P/E29.3

Technical Analysis

TrendNeutral
RSI35.7
Support$45.57
Resistance$62.32
MA 20$55.33
MA 50$58.60
MA 200$48.21
MACDBearish
VolumeStable
Fear & Greed Index76.63

Valuation

Fair Value$121.30
Target Price$71.14
Upside/Downside40.98%
GradeUndervalued
TypeBlend
Dividend Yield4.73%

Risk Assessment

Beta0.77
Volatility46.71%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.